Active Ingredient History
Pevonedistat (MLN4924) is a selective NEDD8 inhibitor. It is being investigated as a cancer treatment, e.g. for mantle cell lymphoma (MCL). Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Cholangiocarcinoma (Phase 2)
Hematologic Neoplasms (Phase 1)
Hodgkin Disease (Phase 1)
Hypercholesterolemia (Phase 3)
Leukemia, Eosinophilic, Acute (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1/Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 3)
Leukemia, Neutrophilic, Chronic (Phase 1/Phase 2)
Leukemia, Prolymphocytic, B-Cell (Phase 1)
Liver Diseases (Phase 1)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1/Phase 2)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Melanoma (Phase 1)
Mesothelioma (Phase 1/Phase 2)
Multiple Myeloma (Phase 1)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasm, Residual (Phase 2)
Neoplasms (Phase 1/Phase 2)
Polycythemia Vera (Phase 1/Phase 2)
Primary Myelofibrosis (Phase 1/Phase 2)
Renal Insufficiency (Phase 1)
Thrombocythemia, Essential (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue